{"id":473953,"date":"2020-03-16T08:42:01","date_gmt":"2020-03-16T08:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=473953"},"modified":"2020-03-16T08:42:01","modified_gmt":"2020-03-16T08:42:01","slug":"herpes-zoster-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/herpes-zoster-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies-by-delveinsight_473953.html","title":{"rendered":"Herpes Zoster Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight"},"content":{"rendered":"
\"Herpes<\/a><\/p>\n
\n
Herpes Zoster Market Insights, Epidemiology, and Market Forecast-2030 <\/div>\n<\/div>\n<\/div>\n
\n<\/div>\n

Albany, US –<\/strong> DelveInsight has launched a new report on Herpes Zoster Market Insights, Epidemiology and Market Forecast-2030  <\/p>\n

 <\/p>\n

DelveInsight’s “Herpes Zoster Market Insights, Epidemiology, and Market Forecast-2030<\/a>” report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

 <\/p>\n

The Herpes Zoster market report provides current treatment practices, emerging drugs, Herpes Zoster market share of the individual therapies, current and forecasted Herpes Zoster market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Herpes Zoster treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

 <\/p>\n

Key benefits of the report
<\/strong>1. Herpes Zoster market report covers a descriptive overview and comprehensive insight of the Shingles epidemiology and Shingles market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Herpes Zoster market report provides insights on the current and emerging therapies.
3. Shingles market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Herpes Zoster market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Herpes Zoster market.<\/p>\n

“Among the Herpes Zoster patients, females show a higher proportion of Herpes Zoster prevalence as compared to males in the 7MM<\/em>.”<\/p>\n

            \"\"<\/p>\n

Request for sample pages here -> https:\/\/www.delveinsight.com\/sample-request\/herpes-zoster-market<\/a><\/p>\n

 <\/p>\n

Shingles (Herpes Zoster), is a viral disease characterized by a painful skin rash with blisters in a localized area. Typically the rash occurs in a single, wide stripe either on the left or right side of the body or face. Two to four days before the rash occurs there may be tingling or local pain in the area. Otherwise, there are typically few symptoms though some may have fever or headache, or feel tired. The rash usually heals within two to four weeks; however, some people develop ongoing nerve pain which can last for months or years, a condition called postherpetic neuralgia (PHN).In those with poor immune function, the rash may occur widely. If the rash involves the eye, vision loss may occur.<\/p>\n

Shingles are caused due to a reactivation of varicella-zoster virus (VZV) in a person’s body. The disease chickenpox is caused by the initial infection with VZV. Once chickenpox has resolved, the virus may remain inactive in nerve cells. When it reactivates, it travels from the nerve body to the endings in the skin, producing blisters. Risk factors for reactivation include old age, poor immune function, and having had chickenpox before 18 months of age. The earliest symptoms of shingles, which include headache, fever, and malaise, are nonspecific and may result in an incorrect diagnosis. Most cases of shingles clear up within 2 to 3 weeks. Shingles rarely occur more than once in the same person, but approximately 1 in 3 people in the United States will have shingles at some point in their life, according to the Centers for Disease Control and Prevention (CDC).<\/p>\n

The launch of the emerging therapies is expected to significantly impact Herpes Zoster treatment scenario in the upcoming years:-
Drugs covered
1. NPC-06
2. CRV-101
3. EG-HZ
And many others<\/p>\n

The key players in Herpes Zoster market are:
1. Nobelpharma
2. GC Pharma
3. EyeGene
And many others<\/p>\n

Request for sample pages here -> https:\/\/www.delveinsight.com\/sample-request\/herpes-zoster-market<\/a><\/p>\n

Table of contents<\/strong>
1. Key Insights
2. Executive Summary of Herpes Zoster
3. Competitive Intelligence Analysis for Herpes Zoster
4. Herpes Zoster Market Overview at a Glance
5. Herpes Zoster Disease Background and Overview
6. Patient Journey
7. Herpes Zoster Epidemiology and Patient Population
8. Country Wise Herpes Zoster Epidemiology
8.1. United States
8.2. EU5 Countries
8.3. Assumptions and Rationale
8.4. Germany
8.5. France
8.6. Italy
8.7. Spain
8.8. United Kingdom
8.9. Japan
9. Herpes Zoster Treatment
10. Herpes Zoster Treatment Algorithm
11. Unmet Needs
12. Herpes Zoster Marketed Drugs
12.1. Shingrix: GlaxoSmithKline
12.2. VARIVAX: Merck Sharp & Dohme Corp
14. Herpes Zoster Emerging Drugs
14.1. Key Cross Competition
14.2. NPC-06:Nobelpharma
14.3. CRV-101: GC Pharma
14.4. EG-HZ: EyeGene
15. Herpes Zoster 7 Major Market Analysis
15.1. Key Findings
15.2. Herpes Zoster market Size in 7MM
16. Attribute analysis
17. The United States Market Outlook
17.1. United States Market Size
18. EU-5 Countries: Market Outlook
18.1. Germany
18.2. France
18.3. Italy
18.4. Spain
18.5. United Kingdom
19. Japan: Market Outlook
20. Access and reimbursement overview of Herpes Zoster
21. KOL Views
22. Market Drivers
23. Market Barriers
24. Appendix
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight<\/p>\n

Related Reports:<\/strong><\/p>\n